-
Hyundai uses BASF polyurethane foam to produce car seats
Time of Update: 2022-08-18
” Hyundai Motor Company's Ulsan plant will exclusively use BASF's Elastoflex polyurethane foam combination to manufacture car seats .
” Hyundai Motor Company's Ulsan plant will exclusively use BASF's Elastoflex polyurethane foam combination to manufacture car seats .
-
The competition for the inhalant market among pharmaceutical companies is fierce, and the industry will be reshuffled
Time of Update: 2022-08-11
Data shows that in 2021, the sales of levalbuterol hydrochloride atomized inhalation solution in public medical institutions in China will increase by more than 3,209% year-on-year, or about 200 million yuan .
-
Centralized procurement and heavy volume have become the highlights of the 2021 annual reports of some "barefoot" pharmaceutical companies
Time of Update: 2022-05-09
In addition, in the first quarter of 2022, the company's performance continued to grow, achieving operating income of 517 million yuan, a year-on-year increase of 42.
The annual report data shows that in the fourth quarter of 2021, the company's operating income reached 689 million yuan, a year-on-year increase of 114.
-
Policies continue to benefit the traditional Chinese medicine industry. How to grasp the main line of future development
Time of Update: 2022-05-09
In addition, traditional Chinese medicine should also adhere to theoretical innovation, clinical services to improve efficacy, effective formulation of prescriptions to transform new drugs, and promotion of industrial development, and then to international development, in order to achieve the modernization, industrialization, internationalization and high-quality development of the traditional Chinese medicine industry .
-
Live preview uses customized excipients to meet new challenges in formulations
Time of Update: 2022-04-16
Thursday, February 24 14:00 - 15:00 IFF Pharmaceutical Solutions Dr.
Gao Hao , an application technology expert in the Asia-Pacific region will discuss with you
-
The 50-day countdown to the Asian Concrete World Expo-the ending battle of 2020, the year-end event of the concrete construction industry
Time of Update: 2022-04-10
WOCA 2020 Asia Concrete World Expo, as the Asian station of the "Concrete World Expo" series, a well-known exhibition brand in the global commercial concrete and construction industry, will be held on December 9-11, 2020 at the Shanghai New International Expo Center, China .
-
China signs annual potash contract with BPC for USD 219 per ton
Time of Update: 2022-03-15
On July 14, the Belarusian Potash Corporation (BPC) announced that it had reached an agreement with the Chinese Buyers Alliance (Sinochem, China Agricultural Materials Group, CNOOC) to supply potash to China at a contract price of US$219 per ton (CFR).
-
In 2022, mergers and acquisitions of biopharmaceutical companies may be more active
Time of Update: 2022-03-06
Among them, in terms of merger and acquisition value, there are at least 4 transactions with a value of more than 10 billion US dollars, including Australian biotechnology companies CSL, Thermo Fisher, Merck and Siemens .
-
In 2021, the pharmaceutical industry will usher in a salary increase
Time of Update: 2021-12-26
As far as the pharmaceutical industry is concerned, according to the "2021 Corporate Salary Adjustment Data Reference Manual" issued by CIIC Consulting in April, in the 2021 survey data, companies have resumed normal operations, and more than 70% of the companies have salary adjustment plans, of which 23 % Of companies’ salary adjustment budgets have increased from last year .
-
Another city
Time of Update: 2021-12-08
On November 9th, Astellas and Baiyang Pharmaceutical have joined hands, and the two parties have discussed the original research drugs of Astellas Betantil (Mirabegron sustained-release tablets), Weixikang (Sorinasine succinate tablets) and The promotion and operation of Halo (tamsulosin hydrochloride sustained-release capsules) in mainland China reached a deepening cooperation agreement, which will jointly explore the commercialization of urinary treatment drugs, improve drug availability, and better serve Chinese patients with urinary diseases .
-
Sinochem International intends to purchase nearly 40% of the shares of Yangnong Group for 7.6 billion yuan
Time of Update: 2021-11-22
Sinochem International stated that through this transaction, the company will further increase its shareholding in the holding subsidiary Yangnong Group.
Sinochem International stated that through this transaction, the company will further increase its shareholding in the holding subsidiary Yangnong Group.
-
Britain faces a shortage of turkeys at Christmas
Time of Update: 2021-11-11
The chairman of the British Poultry Federation Graeme Deere said at a meeting of the relevant committees of the British Parliament that due to the shortage of industry workers, the UK may face a shortage of turkeys at Christmas .
-
The price of "anti-cancer drug" PD-1 penetrates the floor. Why are pharmaceutical companies still pouring into this red sea
Time of Update: 2021-09-19
In this regard, retrospectively, it is believed that even if the drug companies that have already "on the car" are slow to market, they can directly use their own products when they develop new tumor drugs that require PD-1 combination, so as to firmly control it.
-
Tiger Medicine: Tiger Equity intends to invest 9.8 billion yuan to set up a biomedical industry fund
Time of Update: 2021-08-06
Tailong Investment will subscribe RMB 200 million as a general partner and fund manager, with a subscribed capital contribution ratio of 1% .
Tiger Equity is a limited partner of Tailong Investment, with a subscribed capital of RMB 198 million, accounting for 99% of the total capital contribution of Tailong Investment .
-
Baiyunshan Pharmaceutical Amlodipine Besylate Tablets have passed the quality and efficacy consistency evaluation of generic drugs
Time of Update: 2021-07-31
As of the announcement date, Baiyunshan Pharmaceutical General Factory has invested approximately RMB 4,378,800 in research and development expenses (unaudited) for the consistency evaluation of the drug .
